- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Synokem gets CDSCO Panel nod to market Topiroxosatat
New Delhi: Pharmaceutical major Synokem Pharmaceutical has got a green signal from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) to manufacture and market Topiroxosatat Tablet 20/40/60 mg.
This came after the firm presented a proposal for permission to manufacture and market the Topiroxosatat Tablets 20/40/60 mg along with bioequivalence study results.
Topiroxostat, a selective xanthine oxidase inhibitor, shows effective reduction in the serum urate level in hyperuricemic patients with or without gout.
It is developed for the treatment and management of hyperuricemia and gout. Xanthine oxidase inhibitors are classified into two groups, purine analogs such as Allopurinol and Oxypurinol, and non-purine agents which include topiroxostat. Topiroxostat reduces the synthesis of uric acid by competitively inhibiting xanthine oxidase in a selective and time-dependent manner. It helps to reduce the concentration of insoluble urates and uric acid in tissues, plasma, and urine.
Xanthine oxidase, or xanthine oxidoreductase, regulates purine metabolism. The inhibition of the enzyme results in an efficacious reduction of serum urate levels. Topiroxostat covalently binds to and inhibits, molybdenum- pterin, the active center of xanthine oxidase. It also shows properties of inhibition of ATP-binding cassette transporter G2 (ABCG2) in vitro, which is a membrane protein responsible for recovering uric acid in the kidneys and secreting uric acid from the intestines.
Earlier, at the 69th SEC meeting for Reproductive and Urology, in response to the proposal for a clinical trial (CT) waiver along with the bioequivalence (BE) study protocol presented by the drug maker Synokem, the expert panel noted that Topiroxostat tablets 20mg, 40mg, and 60mg are already approved in the country and agreed with the justification submitted for CT waiver and recommended for grant of permission to conduct the BE study as per the protocol presented subject to the condition that the reference arm of the bioequivalence study should be Topiroxostat 60mg tablets only.
Now, in continuation, at the recent SEC meeting for Reproductive and Urology held on July 27,2022, the expert panel reviewed the proposal presented by the firm for permission to manufacture and market the Topiroxosatat.
After detailed deliberation, the committee noted that the drug Topiroxosatat is already approved in the country and opined that the Topiroxosatat Tablet 60mg of Synokem Pharmaceuticals and the reference Topiroxosatat Tablet 60 mg are bioequivalent.
Hence, the committee recommended the grant of permission to manufacture and market Topiroxosatat Tablets 20/40/60 mg.
Doctor of Pharmacy
Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.